Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.New work to include regions of the hemagglutinin molecule
Subscribe to our email newsletter
CEL -SCI is expanding the scope of its work for creating a new treatment and vaccination against the current H1N1 virus, and a future mutated form in which the virus has acquired greater morbidity and mortality. It says that the new work would add regions of the hemagglutinin molecule.
CEL-SCI has two on-going research programs directed towards the H1N1 virus, where the first one deals with a future mutated form of virus. The second program is directed at helping sick patients infected with the current form of H1N1. CEL-SCI is expected to give updated communication on that program within the next month.
The company stated that it is focused on creating a treatment/vaccine against such a virus by combining non-changing parts of the H1N1 virus, the Avian Flu virus and the Spanish Flu virus. When a new virus surfaces, this treatment/vaccine is expected to provide an important cornerstone for the fight against the virus.